International Advance Journal of Engineering, Science and Management (IAJESM)
Multidisciplinary, Indexed, Double Blind, Open Access, Peer-Reviewed, Refereed-International Journal.
SJIF Impact Factor =7.938, July-December 2024, Submitted in September 2024, ISSN -2393-8048

Simultaneous Estimation of Linagliptin and Empagliflozin By RP- HPLC And Validation as Per ICH Guidelines

Jadhav Raviraj R, Research Scholar Sunrise University, Alwar, Rajasthan, India
Vitthal Gajananrao Kuchake, Research Guide Sunrise University, Alwar, Rajasthan, India

Abstract

A simple, specific and sensitive reverse phase high performance liquid chromatographic (RP-HPLC) method was developed and validated for simultaneous determination of linagliptin and empagliflozine in tablet dosage forms.

Chromatography was performed through kromosil (250 x 4.6 mm, 5□) and isocratic elution. Mobile phase containing buffer and acetonitrile in the ratio of 70:30 was pumped through column at a flow rate of 1 ml/min. Buffer used in this method was 0.1% OPA buffer with pH 4.8 adjusted by triethylamine maintained with a temperature of 30°C. Optimized wavelength for linagliptin and empagliflozine was 286 nm. Retention time of linagliptin and empagliflozine were found to be 1.920 min and 3.699 min respectively. %RSD of the linagliptin and empagliflozine were 1.0 and 0.94 respectively. All the validation parameters were in the acceptable range. Simultaneously this method applied to determine the degradation products of linagliptin and empagliflozine. The detection wavelength of 286 nm was chosen in order to achieve high sensitivity for quantitative determination of these drugs in solid dosage form. Method can be successfully employed for simultaneous estimation of these drugs in commercial products.

Key words: linagliptin and empagliflozine, RP HPLC,

Pharmaceutical product quality [1] is of vital importance for patient safety. The presence of impurities may influence the efficacy and safety of pharmaceuticals. Impurities and potential degradation products can cause changing of chemical, pharmacological and toxicological properties of drugs having significant impact on product quality and safety. Drug stability is considered to be the secure way to ensure delivery of therapeutic values to the patients.

Stability is defined as the capacity of a drug substance to remain within the established specifications to maintain its identity, strength, quality and purity throughout the retest or expiration dating period.

Stability of a pharmaceutical/medicinal product is defined as the capability of a particular formulation, in a specific container/closure system, to remain within its physical, chemical, microbiological, therapeutic and toxicological specifications. Pharmaceutical products are expected to meet their specifications for identity, purity, quality and strength throughout their defined storage period at specific storage conditions.

Stability [2] is an essential factor of quality, safety and efficacy of a drug substance. A drug substance, which is not of sufficient stability, can result in changes in physical (like appearance, melting point, clarity and colour of solution, water, crystal modification(polymorphism) or particle size) as well as chemical characteristics (increase in impurities and decrease in assay) and microbiological attributes (Total bacterial count, fungal count and for pathogenic microbes).

The purpose of stability testing is to provide evidence on how the quality of a drug substance varies with time under the influence of a variety of environmental factors such as temperature, humidity, and light, and to establish a retest period for the drug substance and recommended storage conditions. The degree of variability of individual batches affects the confidence that a future production batch will remain within specification throughout the assigned re-test period.

Stability [3] plays an important role in the drug development process. It explains several factors that affect the expiration dating of drug products, including the chemical and physical stability during the pre-clinical formulation stages, process development, packaging development, and post-marketing life. The evaluation of the physicochemical stability of a substance. The two main aspects of drug product that play an important role in shelf life given product requires an understanding of the physical and chemical properties of the drug

determination are assay of active drug and degredents generated during the stability studies.

The container closure system must be evaluated for compatibility with the drug substance and drug product to ensure that the container and closure system does not contribute to degradation or contamination.

MATERIALS AND METHODS

Materials:

Linagliptin and Empagliflozin, Combination Linagliptin and Empagliflozin tablets, distilled water, acetonitrile, phosphate buffer, ammonium acetate buffer, glacial acitic acid, methanol, potassium dihydrogen phosphate buffer, tetra hydrofuran, tri ethyl amine, ortho-phosphoric acid etc.

Instrument:

HPLC instrument used was of WATERS HPLC 2965 SYSTEM with Auto Injector and PDA Detector. Software used is Empower 2. UV-VIS spectrophotometer PG Instruments T60 with special bandwidth of 2mm and 10mm and matched quartz was be used for measuring absorbance for Linagliptin and Empagliflozin solutions

Methods:

Preparation of buffer:

Buffer: (0.1 %OPA)

1 ml of con. OPA is dissolved in 1000 ml volumetric flask diluted with distilled water up to the mark. pH adjusted to 4.8 by using Triethylamine

Standard Preparation:

Accurately Weighed and transferred 12.5mg&25mg of Linagliptin and Empagliflozine working Standards into a 25ml and 25ml clean dry volumetric flask respectively, add 20ml and 20ml of diluent, sonicated for 30 minutes and make up to the final volume with diluents. From the above stock solutions, 1ml was pipette out in to a 10ml volumetric flask and then make up to the final volume with diluent.

Sample Preparation:

5 tablets were weighed and calculate the average weight of each tablet then the weight equivalent to 1 tablet was transferred into a 10 ml volumetric flask, 7ml of diluent added and sonicated for 30 min, further the volume made up with diluent and filtered. From the filtered solution 1ml was pipette out into a 10 ml volumetric flask and made up to 10ml with diluent.

METHOD DEVELOPMENT

Method Development: Many trials were done by changing columns and Mobile phases and were reported below.

Column Used : ODS 250 x 4.6 mm, 5µ.
Mobile phase : water: Acetonitrile methanol (30:50:20)
Flow rate : 1ml/min
Wavelength : 285 nm
Temperature : 30°C
Injection Volume : 10µl

RESULTS AND DISCUSSION

1. **System suitability:** All the system suitability parameters are within range and satisfactory as per ICH guidelines

Table: 1 System suitability studies of Linagliptin and Empagliflozine method

Property	Linagliptin	Empagliflozine
Retention time (t_R)	1.920min	3.690min
Theoretical plates (N)	7217 ± 63.48	8554 ± 63.48
Tailing factor (T)	1.08 ± 0.117	1.22± 0.117



Fig : 1 Chromatogram of blank.



Fig: 2 Typical chromatogram of Linagliptin and Empagliflozin.

2. Linearity: Six Linear concentrations of Linagliptin (12.5-75µg/ml) and Empagliflozin
(25-150 µg/ml) are prepared and Injected. Regression equation of the Linagliptin and Empagliflozin are found to be, y = 9531.x + 4618, and y = 37150x + 745.2. And regression co-efficient was 0.999.

Table 2 Calibration data of Linagliptin and Empagliflozin method.

S. No	Concentration Linagliptin	Response	Concentration Empagliflozin	Response
1	0	0	0	0
2	25%	126420	25%	905911
3	50%	245671	50%	1934386
4	75%	367825	75%	2778580
5	100%	477424	100%	3645445
6	125%	593849	125%	4628418
7	150%	723119	150%	5616375



Fig: 3 Calibration curve of Linagliptin



Fig: 4 Calibration curve of Empagliflozin

3. Precision:

Intraday precision (Repeatability): Intraday Precision was performed and % RSD for Linagliptin and Empagliflozin were found to be 1.0% and 0.94% respectively.

Table: 3 Repeatability results for Linagliptin and Empagliflozin .

Sr. No.	Linagliptin	Empagliflozin
1	462762	3598346
2	463892	3598711
3	467252	3587845
4	469414	3565861
5	473880	3656485
6	472737	3563766
Mean	468323	3595169
Std. Dev.	4544.4	33708
%RSD	1.0	0.94

*Average of six determinations

Inter day precision: Inter day precision was performed with 24 hrs time lag and the %RSD Obtained for Linagliptin and Empagliflozin were 0.60% and 0.43%.

Table 4 Inter day precision results for Linagliptin and Empagliflozin .

Sr. No.	Linagliptin	Empagliflozin
1	457175	3611613
2	457484	3572397
3	459261	3587699
4	464175	3598528
5	459196	3574390
Mean	459155	3590575
Std. Dev.	2616	15326
%RSD	0.6	0.43



Fig: 5 Inter Day precision Chromatogram of Linagliptin and Empagliflozin

4. Accuracy: Three concentrations 50%, 100%, 150%, were injected in a triplicate manner and amount Recovered and % Recovery were displayed in Table 6.5.

Table: 6 Table of Accuracy

Sample	Concentration (%)(µg/ml)	Amount Recovered (µg/ml)	Recovery (%)	% RSD
	25	25.28	101.11	0.94
	50	49.89	99.79	0.54

Linagliptin	75	75.15	100.20	0.25
Empagliflozin	50	50.56	101.12	0.57
	100	100.58	100.58	0.85
	150	151.06	100.71	0.34

5. LOD: Limit of detection was calculated by std deviation method Linagliptin and Empagliflozin and LOD for Linagliptin and Empagliflozin were found to be 0.24and 0.17respectively.



Fig : 6 LOD Chromatogram of Linagliptin and Empagliflozin

6. LOQ: Limit of Quantification was calculated by std deviation method Linagliptin and Empagliflozin and LOQ for Linagliptin and Empagliflozin were found to be 0.72 and 0.51 respectively.



Fig : 7 LOQ Chromatogram of of Linagliptin and Empagliflozin

7. **Robustness:** Small deliberate changes in method like Flow rate, mobile phase ratio, and temperature are made but there were no recognized change in the result and are within range as per ICH Guide lines.

Table 7 Robustness data of Linagliptin and Empagliflozin

S.NO	Robustness condition	Linagliptin %RSD	Empagliflozin %RSD
1	Flow minus	1.34	0.65
2	Flow Plus	0.75	0.20
3	Mobile phase minus	0.23	0.26
4	Mobile phase Plus	0.02	0.15
5	Temperature minus	0.94	0.66
6	Temperature Plus	1.36	0.06

Assay: Standard preparations are made from the API and Sample Preparations are from Formulation. Both sample and standards are injected six homogeneous samples. Drug in the formulation was estimated by taking the standard as the reference. The Average %Assay was calculated and found to be 100.63% and 100.20% for Linagliptin and Empagliflozin respectively.

Table 8 Assay of Tablet

S. No.	Linagliptin %Assay	Empagliflozin %Assay
1	99.44	100.29

2	99.68	100.30
3	100.40	100.00
4	100.87	99.38
5	101.83	101.91
6	101.58	99.33
AVG	100.63	100.20
STDEV	0.9765	0.9395
%RSD	1.0	0.94



Fig: 8 Assay of Tablet

Degradation Studies: Degradation studies were performed with the formulation and the degraded samples were injected. Assay of the injected samples was calculated and all the samples passed the limits of degradation

Table 9 Degradation Data of LINAGLIPTIN

S.NO	Degradation Condition	AREA	% ASAAY	AMOUNT DEGRADED %
1	Acid	452252	97.18	2.82
2	Alkali	459880	98.82	1.18
3	Oxidation	449176	96.52	3.48
4	Thermal	462236	99.32	0.68
5	UV	461745	99.22	0.78
6	Water	463578	99.61	0.39

Table 10 Degradation Data of EMPAGLIFLOZIN

S.NO	Degradation Condition	AREA	%ASSAY	AMMOUNT DEGRADED %
1	Acid	3503766	97.65	2.35
2	Alkali	3528711	98.35	1.65
3	Oxidation	3486053	97.16	2.84
4	Thermal	3561306	99.26	0.74
5	UV	3551594	98.99	1.01
6	Water	3564912	99.36	0.64

SUMMARY AND CONCLUSION

Table 11 Summary

Parameters	Linagliptin	Empagliflozin
Calibration range (mcg / ml)	12.5-75 ppm	25-150 ppm
Optimized wavelength	210nm	210nm
Retention time	1.920min	3.699 min
Regression equation (Y*)	y = 9531.x + 4618.	y = 37150x + 745.2

Correlation coefficient(r^2)	0.999	0.999
Precision (% RSD*)	1.0	0.94
% Assay	100.63%	100.20%
Limit of Detection (mcg / ml)	0.24ppm	0.17ppm
Limit of Quantization (mcg / ml)	0.72ppm	0.51ppm

Conclusion

A simple, Accurate, precise method was developed for the simultaneous estimation of the Linagliptin and Empagliflozin in Tablet dosage form. Retention time of Linagliptin and Empagliflozin were found to be 1.920min and 3.699 min. %RSD of the Linagliptin and Empagliflozin were and found to be 1.0 and 0.94 respectively. %assay was obtained as 100.63% and 100.20% for Linagliptin and Empagliflozin respectively. LOD, LOQ values are obtained from regression equations of Linagliptin and Empagliflozin were 0.24ppm, 0.72ppm and 0.17ppm, 0.51ppm respectively. Regression equation of Linagliptin and Empagliflozin is

y = 9531.x + 4618, and y = 37150x + 745.2 Retention times are decreased and that run time was decreased so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.

REFERENCE

1. R. S. Satoskar, S. D. Bhandarkar and S. S. Ainapure. "Pharmacology and Pharmacotherapeutics", 17th edition, Popular Prakashan, Mumbai, India, 2001.
2. G. Ramana Rao, S. S. N. Murthy and P. Khadgapathi. Gas chromatography to pharmaceutical analysis (Review). Eastern Pharmacist. 30(353): 35 (1987).
3. G. Ramana Rao, S. S. N. Murthy and P. Khadgapathi. High performance liquid chromatography and its role in pharmaceutical analysis (Review). Eastern Pharmacist. 29 (346): 53 (1986).
4. Ll-Yord R. Snyder, Joseph J. Kirkland and Joseph L. Glajch. Practical HPLC Method development. John Wiley & Sons, INC, U.S.A. 2 nd Edition, New York, 1997.
5. Satinder Ahuja and Michael W. Dong. Handbook of Pharmaceutical Analysis by HPLC, Elsevier academic press, 1 st Edition, Vol. 6, 2005.
6. M. Thompson, S. L. R. Ellison and R. Wood. Harmonized guidelines for single laboratory validation of methods of analysis. Pure Appl. Chem. 74(5): 835- 855(2002)8
7. USP 31/NF 26, United States Pharmacopoeia, 31st rev. and the National Formulary, 26 ed. United States Pharamcopoeial Convention, Rockville, 2008.
8. Scheen AJ: Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clin Pharmacokinet. 2015 Mar 25.
9. Gangadharan Komala M, Mather A: Empagliflozin for the treatment of Type 2 diabetes. Expert Rev Clin Pharmacol. 2014 May;7(3):271-9. doi: 10.1586/17512433.2014.908703. Epub 2014 Apr 9.
10. Lamos EM, Younk LM, Davis SN: Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2014 Jun;23(6):875-82. doi: 10.1517/13543784.2014.909407. Epub 2014 Apr 19.